Press Release
« Back
TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
Nov 02, 2020
ASH 2020 PRESENTATION DETAILS:
- Oral Presentation Title: Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study
° Publication Number: 543
° Oral Session: 642. CLL: Therapy, excluding Transplantation
° Session Date and Time:Monday, December 7, 2020 ;7:00 AM –8:30 AM (Pacific Time)
- Presentation Time:7:15 AM (Pacific Time)
° Presenter:John G. Gribben ,D.Sc ., F.R.C.P.,F.R.C.Path ., F.Med.Sci., North East London Cancer Research Network Centre, Barts and theLondon Cancer Center ,UK
- Poster Presentation Title: Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial
° Publication Number: 2934
° Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
° Date and Time:Monday, December 7, 2020 ;7:00 AM - 3:30 PM (Pacific Time)
° Presenter: Pier Luigi Zinzani, MD,Institute of Hematology , “L. e A. Seràgnoli”,University of Bologna, Italy
- Poster Presentation Title: A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) ° Publication Number: 3137
° Session: 642. CLL: Therapy, excluding Transplantation: Poster III
° Date and Time:Monday, December 7, 2020 ;7:00 AM - 3:30 PM (Pacific Time)
° Presenter:Paul M. Barr , MD,Wilmot Cancer Institute ,University of Rochester Medical Center , NY
- Poster Presentation Title: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies
° Publication Number: 1130
° Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
° Date and Time:Saturday, December 5, 2020 ;7:00 AM - 3:30 PM (Pacific Time)
° Presenter:Chan Cheah , MD,Sir Charles Gairdner Hospital ,Hollywood Private Hospital ,University of Western Australia , Blood Cancer Research Western Australia
Abstracts will be made publicly available online on
ZOOM CONFERENCE CALL INFORMATION
The Company will host a zoom conference call
In order to participate in the call, please join via the zoom webinar link: https://bit.ly/37XZai1, which will also be available on the Events page, located within the Investors & Media section, of the Company's website at https://ir.tgtherapeutics.com/events. Attendees may also join via phone by dialing 1-877-407-8029 (
ABOUT
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in late stage clinical development with two investigational compounds, ublituximab and umbralisib, the combination of which is referred to as “U2”, targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. Umbralisib (TGR-1202) is an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon. Umbralisib is currently under review by the U.S. Food and Drug Administration (FDA) for accelerated approval as a treatment for patients with previously treated marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen or follicular lymphoma (FL) who have received at least two prior systemic therapies. The Company also has a fully enrolled Phase 3 clinical trial evaluating U2 in patients with treatment naïve and relapsed/refractory chronic lymphocytic leukemia (CLL), and two fully enrolled identical Phase 3 trials evaluating ublituximab monotherapy in patients with relapsing forms of multiple sclerosis (RMS). Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.
Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In addition to the risk factors identified from time to time in our reports filed with the
CONTACT:
Senior Vice President,
Corporate Communications
Telephone: 212.554.4351
Email: ir@tgtxinc.com
Source: TG Therapeutics, Inc.